You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
Dow
Medtronic
Johnson and Johnson

Last Updated: May 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Hydrochlorothiazide; Quinapril Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00515021 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status National Center for Research Resources (NCRR) Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma PAI-1 levels more effectively than morning administration.
NCT00515021 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status Vanderbilt University Medical Center Phase 4 2007-04-01 To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma PAI-1 levels more effectively than morning administration.
NCT00648011 Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 2003-08-01 The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20mg/ 25 mg tablets following a single, oral 20/25 mg (1 x 20/25 mg) dose administration under fed conditions.
NCT00649441 Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 2003-08-01 The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting conditions.
NCT00651287 A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension Completed Pfizer Phase 4 2002-12-01 The purpose of this study is to determine the response rate for the therapeutic goal (diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week 6 for quinapril 20 mg and at Week 12 for quinapril 20 mg, quinapril 40 mg, and quinapril 20 mg plus hydrochlorothiazide 12.5 mg; and to determine the mean decrease in diastolic and systolic BP measurements and the change in heart rate at Week 6 and Week 12 compared with baseline.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrochlorothiazide; Quinapril Hydrochloride

Condition Name

Condition Name for Hydrochlorothiazide; Quinapril Hydrochloride
Intervention Trials
Healthy 4
Hypertension 2
Type 2 Diabetes Mellitus 1
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Quinapril Hydrochloride
Intervention Trials
Hypertension 2
Diabetes Mellitus, Type 2 1
Diabetes Mellitus 1
Metabolic Syndrome X 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrochlorothiazide; Quinapril Hydrochloride

Trials by Country

Trials by Country for Hydrochlorothiazide; Quinapril Hydrochloride
Location Trials
United States 3
India 2
Turkey 2
Romania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrochlorothiazide; Quinapril Hydrochloride
Location Trials
North Dakota 2
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrochlorothiazide; Quinapril Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Quinapril Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 1 2
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Quinapril Hydrochloride
Clinical Trial Phase Trials
Completed 6
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrochlorothiazide; Quinapril Hydrochloride

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Quinapril Hydrochloride
Sponsor Trials
Ranbaxy Laboratories Limited 2
Mylan Pharmaceuticals 2
LaborMed Pharma S.A. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Quinapril Hydrochloride
Sponsor Trials
Industry 6
Other 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Medtronic
Moodys
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.